Özgeçmiş
Hematoloji
Hematolojik Onkoloji
Aferez
Kök Hücre Nakli
Sorularınız
Seminerler
Ders 2008
Homer
Linkler
Son Gelişmeler
Halk İçin Hematoloji
Aktiviteler
 
   
   
   

Geri


YAYINLANMIŞ OLAN ULUSLARARASI KONGRE ABSTRAKTLARI

  1. Şardaş OS, Beksaç M, Akan H, Koç H, İlhan O. Addition of Verapamil to overcome drugresistance in refractory hematological malignancies. J Can Res Clin Oncol 116 (suppl 1):416, 1990.

  2. Şardaş O.S., Beksaç M., Akan H., Koç H., İlhan O. Imbalances within the peripheral blood lymphocyte subpopulation in the reconstitution phase after bone marrow transplantation. Bone marrow transplantatıon 5 (suppl 2): 144, 1990.

  3. Şardaş O.S., Koç H., İlhan O., Akan H., Beksaç M. Family mismatched donors in allogeneic bone marrow transplantation. Bone marrow transplantation 5 (suppl 2): 150, 1990.

  4. Şardaş O.S., Koç H., İlhan O., Akan H., Beksaç M. High dose chemotherapy and autologous bone marrow transplantation in refractory malign lymphomas. Bone Marrow Trans 5 (suppl 2): 154, 1990.

  5. Şardaş O.S., Beksaç M., İlhan O., Koç H., Akan H., Gürman G., Ertürk P., Güneyli A. Clinical effects of Ciclosporin A containing chemotherapy protocols in refractory hematological neoplasms. Schweiz Med Woch 121: (Suppl 43) 236, 1991.

  6. Şardaş O.S., Beksaç M., Koç H., Akan H., İlhan O., Gürman G., Özcan M., Güneyli A. Follow up of allogeneic bone marrow transplants with granulocyte colony stimulating factor, tumor necrosis factor alpha and soluble interleukin 2 receptor levels. Schweiz Med Woch 121: (Suppl 43) 272, 1991.

  7. Şardaş O.S., İlhan O., Koç H., Beksaç M., Akan H., Gürman G., Arslan Ö., Konuk N.: Mitoxantrone + Etoposide and Mitoxantrone + High dose cytosine arabinoside in refractory or early relapsed acute leukemias. Schweiz Med Woch 121: (Suppl 43) 240, 1991.

  8. Şardaş OS, Koç H, Beksaç M, İlhan O, Akan H, Gürman G, Özcan M. Interferon-alpha2b(IFNa-2b) therapy and monitorization of serum IL-2R, TNF, G-CSF and GM-CSF in chronic myelogenous leukemia. The European Journal of Cancer 1991 (suppl 2):1380a

  9. İlhan O, Özcan M, Beksaç M, Koç H, Akan H, Konuk N, Uysal A. Treatment of Evans Synsrome with danazol and cyclosporine A. Blood 1993

  10. İlhan O, Özcan M, Koç H, Beksaç M, Akan H, Gürman G, Aydoğdu İ, Konuk N. Danazol therapy in chronic ITP: The preliminary results of İbn-i Sina Group. La Revista De Investigation Clinica 1994, Suppl April:616a

  11. Akan H, Beksaç M, İlhan O, Koç H, Gürman G, Özcan M. Correlation of stem cell factor and soluble adhesion molecules with blast counts in patients undergoing chemotherapy. Blood 1994, 84(10) Suppl 1:a

  12. Beksaç M, Akan H, Koç H, İlhan O, Özcan M. Circulating soluble CD44 and ICAM-1 levels in low grade non-Hodgkin's lymphoma patients during interferon-a treatment. Blood 1994, 84(10) Suppl 1:a

  13. Gürman G, Koç H, Akan H, İlhan O, Beksaç M, Konuk N, Uysal A, Özcan M, Sunguroğlu. Reinduction of remission by immunotherapy in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995, 15 (Suppl 2):73a

  14. Akan H, Koç H, Beksaç M, İlhan O, Gürman G, Konuk N, Uysal A, Özcan M. The effect of HLA in the development of venoocclusive disease in MHC matched adults undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1995, 15 (Suppl 2):370a

  15. Koç H, Akan H, İlhan O, Gürman G, Özcan M, Arslan Ö, Beksaç M, Konuk N, Uysal A. Relationship between serum cytokine levels and aplasia period following high dose chemotherapy supported by granulocyte-colony stimulating factor as a salvage chemotherapy without stem cell rescue in malignant lymphomas. Blood 1995, 86(10) Suppl 1:2779a

  16. İlhan O, Arslan Ö, Koç H, Beksaç M, Akan H, Gürman G, Özcan M, Konuk N, Uysal A. High dose epirubicin containing CEOP regimen in intermediate or high grade nonHodgkin's lymphoma. Blood 1995, 86(10) Suppl 1:3245a

  17. Akan H, Şengül Ş, Beksaç M, Koç H, İlhan O, Gürman G, Özcan M. Soluble adhesion molecules during progenitor cell engraftment. Blood 1995, 86(10) Suppl 1:3887a

  18. Bone Marrow Transplantation Activity of Ibni Sina Hospital Turkish J of Haematology 1996,

  19. Koç H, Gürman G, Akan H, Beksaç M, Konuk N, İlhan O, Özcan M, Arslan Ö, Uysal A. Allogeneic peripheral blood stem cell transplantation Turkish J of Haematology 1996,

  20. Beksaç M, Beksaç S, Akan H, Ünal E, İlhan O, Arslan Ö, Koç H, Özcan M, Yalçın S, Gürgey A,, Altay Ç. Cord blood stem cell transplantation for the treatment of beta thalassemia major: a case report Turkish J of Haematology 1996,

  21. Gürman G, Koç H, Akan H, İlhan O, Özcan M, Arslan Ö, Sunguroğlu A, Konuk N, Beksaç M, Uysal A Donor mononuclear cells infusion and alfa interferon administration in rlapsed chronic myeloid leukemia patients after allogeneic bone marrow transplantation Turkish J of Haematology 1996,

  22. İlhan O, Akan H, Koç H, Gürman G, Arslan Ö, Özcan M, Erdi H, Erdem C, Konuk N, Uysal A, Beksaç M Incidence of graft versus host disease in allogeneic bone marrow transplantation in a single center study from Turkey Turkish J of Haematology 1996,

  23. Akan H, Koç H, Arslan Ö, Beksaç M, İlhan O, Gürman G, Özcan M, Üstün C, Konuk N, Uysal A Febrile neutropenia in bone marrow transplantation Turkish J of Haematology 1996,

  24. İlhan O, Koç H, Akan H, Gürman G, Arslan Ö, Özcan M, Arıkan N, Sencer H, Konuk N, Uysal A, Beksaç M Hemorrhagic cystitis as a complication of bone marrow transplantation Turkish J of Haematology 1996,

  25. İlhan O, Beksaç M, Arslan Ö, Koç H, Akan H, Gürman G, Özcan M, Konuk N, Uysal A HLA DR2; a predictive marker in response to immunosupressive therapy in aplastic anemia Turkish J of Haematology 1996,

  26. Özcan M, Beksaç M, Akan H, Arslan Ö, Koç H, İlhan O, Arat M, Konuk N, Uysal A Serum erytropoietin changes associated with erytroid and megkaryocytic engraftment after bone marrow transplantation Turkish J of Haematology 1996,

  27. İlhan O, Beksaç M, Koç H, Akan H, Arslan Ö, Gürman G, Özcan M, Konuk N, Uysal A. HLA DR2 is more frequent among Turkish aplastic anemia patients responding to immunosuppressive therapy. Bone Marrow Transplantat 1996, 17 (Suppl 1):190a

  28. Özcan M, Beksaç M, Akan H, Arslan Ö, Koç H, İlhan O, Arat M, Konuk N, Uysal A. Serum erythropoietin changes associated with erythroid and megakaryocytic engraftment after bone marrow transplantation. Bone Marrow Transplantat 1996, 17 (Suppl 1):205a

  29. Beksaç M, Koç H, Akan H, İlhan O, Özcan M, Arslan Ö, Konuk N, Uysal A, Ataç B. Interphase in situ hybridization for follow-up of engraftment origin and minimal residual disease in bone marrow transplantation patients. Bone Marrow Transplant 1996, 17 (Suppl 1):378a

  30. Koç H, Gürman G, Akan H, Beksaç M, Konuk N, İlhan O, Özcan M, Arslan Ö. Uysal A. Allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 1996, 17 (Suppl 1):506a

  31. İlhan O, Beksaç M, Koç H, Akan H, Arslan Ö, Gürman G, Özcan M, Konuk N, Uysal A HLA DR2; a prognostic factor in response to immunosupressive therapy in aplastic anemia Brit J Haematol 1996,

  32. Akan H, Koç H, Arslan Ö, Beksaç M, İlhan O, Gürman G, Özcan M, Üstün C, Konuk N, Uysal A Febrile Neutropenia in a Bone Marrow Transplantation Unit Brit J Haematol 1996,

  33. İlhan O, Özcan M, Beksaç M, Koç H, Akan H, Kutlay S, Dalva K, Gürman G, Arslan Ö, Arat M, Konuk N, Uysal A The relation of HLA phenotype and survival after allogeneic bone marrow transplantation in turkish patients with chronic myelogenous leukemia (CML). Intl J Hematol 1996, 64 (Suppl 1):292a

  34. Koç H, Akman N, Özcan M, Tunalı A, Ferhanoğlu B, Yücel İlhan O, Beksaç M, Aydın Y, Akan H, Konuk N, Aktuğlu G, Gürman G, Ülkü B, Aydoğdu İ The combination opf chemotherapy with interferon alfa2-b for remission maintenance in multiple myeloma does not prolong remission duration:a multicenter study. Int J Hematol 1996, 64 (Suppl 1):231a

  35. Beksaç M, Arat M, Özcan M, Arslan Ö, Koç H, Akan H, İlhan O, Gürman G, Konuk N, Uysal A. Comparison of peripheral blood, lymph node and bone marrow lymphocyte surface antigens, adhesion molecules in B-CLL and low-grade non-hodgkins lymphoma (NHL). Blood 1996; 88 (10) Suppl 1 (part 1 of 2); 958a

  36. İlhan O, Beksaç M, Arslan Ö, Akan H, Koç H, Dilek İ, Arat M, Özcan M, Gürman G, Konuk N, Uysal A. CD34 cell dose influences hematological recovery after peripheral blood stem cell transplantation. Blood 1996; 88 (10) Suppl 1 (part 2 of 2); 3751a

  37. Üstün C, Koç H, Karayalçın S, Akyol G, Gürman G, İlhan O, Akan H, Özcan M, Arslan Ö, Konuk N, Uysal A, Beksaç M. Hepatic complications of allogeneic bone marrow transplantation. Blood 1996; 88 (10) Suppl 1 (part 2 of 2); 3815a

  38. İlhan O, Özcan M, Beksaç M, Koç H, Akan H, Kutlay S, Dalva K, Gürman G, Arslan Ö, Arat M, Dilek İ, Konuk N, Uysal A. The prognostic relevance of HLA phenotype in allogeneic bone marrow transplantation in Turkish patients with chronic myelogenous leukemia (CML). Blood 1996; 88 (10) Suppl 1 (part 2 of 2);3825a

  39. Arslan Ö, Özcan M, Dilek İ, Gürman G, İlhan O, Akan H, Koç H, Konuk N, Uysal A, Beksaç M. Comparison of peripheral blood stem cell versus bone marrow transplantation results in acute non-lymphoblastic leukemia. BMT 1997: 19(Supl1), 395a

  40. İlhan O, Beksaç M, Arslan Ö, Akan H, Koç H, Dilek İ, Arat M, Özcan M, Gürman G, Konuk N, Uysal A. Stem cell quantity influences engraftment after peripheral blood stem cell transplantation. BMT 1997:19(Supl1), 467a

  41. Üstün C, Karayalçın S, AkyolG, Gürman G, İlhan O, Akan H, Özcan M, Arslan Ö, Konuk N, Uysal A, Beksaç M, Koç H. Hepatitis B virus infection in allogeneic bone marrow transplantation. BMT 1997:19(Supl1), 673a

  42. Koç H, Gürman G, Arslan Ö, Özcan M, Akan H, İlhan O,Konuk N, Uysal A, Beksaç M. Allogeneic peripheral blood stem cell transplantation : An increased risk of GVHD. BMT 1997:19(Supl1), 739a

  43. Marsh J, Schrezenmeier H, Marin P, Ilhan O, Ljungman P, McCann S, SocieG, Tichelkli A, Hows J, Raghavaclar A, Bacigalupo A, on behalf of the EBMT Severe Aplastic Anemia Working Party Interim analysis of prospective randomised study of comparing cyclosporin with the combination of antithymocyte globulin and cyclosporin for the treatment nono severe aplastic anemia. BMT 1997:19(Supl1), O355a

  44. Arslan Ö, Seferoğlu A, Gürman G, İlhan O, Koç H. Resistant graft failure overcome with allogeneic peripheral blood plus bone marrow stem cells. BMT 1997:19(Supl1), 466a

  45. Akar H, Özcan M, Arslan Ö, İlhan O, Koç H, Akan H, Gürman G, Dalva K, Konuk N, Uysal A, Beksaç M. Changes in the natural anticoagulants following hemapoietic stem cell transplantation. BMT 1997:19(Supl1), 738a

  46. Akan H, Dalva K, Üstün C,Koç H, İlhan O, Uysal A, Özcan M,Beksaç M. Surface adhesion molecules in peripheral stem cells of healthy donors primed with G-CSF. Blood 1997, 90(10):170b (Suppl 1).

  47. Kutlay S, Beksaç M, Dalva K, İlhan O, Akan H, Koç H, Özcan M, Konuk N, Uysal A. Clinical relevance of flow cytometric BCL-2 and CD95 expression in acute myeloid leukemia. Blood 1997, 90(10):217b (Suppl 1).

  48. Beksaç M, Tunalı , Akoğlu T, Dündar S, Paydaş S, İlhan O, Koç H, Özcan M, Ovalı E, Uysal A, Yalçın A, Akman N, Büyükkeçeci F. A phase III randomized multicenter study of induction with or without G-CSF followed by intensive consolidation versus stem cell transplantation (PBSCT) in AML (Preliminary results of Turkish Leukemia Study Grou TLG95-002). Blood 1997, 90(10):237b (Suppl 1).

  49. Beksaç M, Arslan Ö, Koç H, Akan H, İlhan O, Arat M, Özcan M,Gürman G Konuk N,Uysal A A randomized single instutional study on comparison of idarubicin (I) versus daunorubicin (D) versus mitoxantrone (M) containing induction and consolidation regimens in acute myeloblastic leukemia (AML). Blood 1997, 90(10):237b (Suppl 1).

  50. İlhan O, Özcan M, Yalçın A, Koç H, Beksaç M, Ünal A, Tunalı A, Gülbaş Z, Gürman G, Dündar S, Ündar L, Payzın B, Akan H. Hematological and cytogenetic efficiency of interferon alpha 2a plus low dose cytarabine in chronic myelogenous leukemia. An interim analysis of multicenter study. Blood 1997, 90(10):278b (Suppl 1).

  51. Gürman G, Arslan Ö, Koç H, Dilek İ, Üstün C, Özcan M, Akan H, İlhan O, Sunguroğlu A, Konuk N, Uysal A, İdilmam R, Beksaç M. Donor leukocyte infusions for the treatment of leukemia relapse after allogeneic hematopoietic progenitor cell transplantation. Blood 1997, 90(10):379b (Suppl 1).

  52. Kutlay S, Beksaç M, Dalva K, İlhan O, Koç H, Akan H, Özcan M, Konuk N, Uysal A. Flow cytometric G-CSF receptor expression in acute myeloid Leukemia and role in G-CSF use at induction chemotherapy. Br J Haematol 102(1):87 1998.

  53. Beksaç M, Arslan Ö, Koç H, Akan H, İlhan O, Arat M, Özcan M, Gürman G, Konuk N, Uysal A. Randomized unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukemia. Br J Haematol 102(1):220 1998.

  54. Beksaç M, İlhan O, Uysal A, Koç H, İdilman R, Arat M, Üstün C, Özcan M. Cladribine Therapy in chronic lymphoproliferative disorders:single center experience. Br J Haematol 102(1):244 1998.

  55. Beksaç M, Üstün C, Özcan M, Koç H, İlhan O, Özçelik T, Dalva K, Gürman G, Akan H, Arat M, Konuk N, Uysal A. Allogeneic peripheral blood stem cell transplants cause more chronic graft versus host disease and less relapse compared to bone marrow transplants. Bone Marrow Transplant 21(Suppl 1):119 1998.

  56. A.Ates, O. Ilhan, M. Özcan, K. Dalva, N. Uğur, M. Beksaç, H. Akan , H. Koç The presence of clonal B cell excess as an indicator of advanced disease and poor survival in patients with multiple myeloma. Blood, 92(10) , (Suppl1):259b (abstrakt:4120) , 1998

  57. Özcan, C. Üstün, O. İlhan, M. Beksaç, E. Akçağlayan, G. Gürman, H. Akan, T.Demirer, M. Arat, H. Çelebi, N. Konuk, A. Uysal, H. Koç The effect of G-CSF in the first 100 days of allogeneic peripheral blood stem cell transplantation. Blood, 92(10) (Suppl2), 326b (abstrakt:4405), 1998

  58. A.Ateş, O. İlhan, M. Özcan, K. Dalva, N. Ugur, M. Beksaç, H. Akan, H. Koç T cell subsets in multiple myeloma: Relation to clinical phase and stage of disease and prognosis Blood, , 92(10) (Suppl 2), 260b (abstrakt:4121), 1998

  59. O. İlhan, M. Özcan, A. Yalçın, H. Koç, M. Beksaç, A. Ünal, A. Tunalı, G. Gürman, S. Dündar, L. Ündar, B. Payzın, H. Akan Interferon alfa 2a and low dose cytarabine in chronic myeloid leukemia: Second interim analysis of multicenter study Blood 92(10) (Suppl 2), 246b (abstrakt:4056), 1998

  60. Ateş, O. İlhan, M. Özcan, K. Dalva, N. Ugur, M. Beksaç, H. Akan, H. Koç Increased CD38 expression on peripheral blood lymphocytes associated with more advanced disease and poor survival in multiple myeloma patients Blood, 92(10) (Suppl2), 259b (abstrakt:4119), 1998

  61. Üstün, M. Beksaç, K. Dalva, N. Konuk, H. Koç, O. İlhan, G. Gürman, H. Akan, M. Arat, H. Çelebi, A. Uysal Effect of in vivo use of all-trans retinoic acid (ATRA) as a single agent on expression of bcl-2 and rhodamine uptake in patients with de novo acute myeloblastic leukemia Blood, 92(10) (Suppl2), 197b (abstrakt:3838), 1998

  62. Üstün, M. Özcan, M. Beksaç, O. İlhan, M. Çakır, G. Gürman, H. Akan, T. Demirer, M. Arat, H. Çelebi, N. Konuk, A. Uysal, H. Koç Clinical effects of intravenous immune globulin (IVIG) treatment in patients with allogeneic peripheral blood stem cell transplantation Blood, 92(10) (Suppl2), 354b (abstrakt:4528), 1998

  63. Beksaç, M. Arat, H. Akan, H. Koç, O. İlhan, M. Özcan Circulating CD44 and ICAM-1 levels in low grade non-hodgkin's lymphoma and B-CLL patients during interferon alpha 2a treatment Blood 92(10) (Suppl 2), 221b (abstrakt:3947), 1998

  64. Gürman, H. Çelebi, C. Üstün, M. Arat, O. İlhan, M. Özcan, Ö. Arslan, A, Uysal, H. Akan, M. Beksaç, N. Konuk, H. Koç Allogeneic peripheral blood stem cell transplantation in patients with severe aplastic anemia Blood 92(10) (Suppl2), 350b (abstrakt:4508), 1998

  65. Gürman, C. Üstün, Ö. arslan, M. Beksaç, N. Konuk, M. Arat, H. Çelebi, M. Özcan, O. İlhan, T. Demirer, H. Akan, A. Uysal, H. Koç Allogeneic hematopoietic stem cell transplantation in patients with advanced hematological malignanciec by using nonmyeloablative conditioning regimen Blood, 92(10) (Suppl2), 350b (abstrakt:4509), 1998

  66. H.Ş. Çoşkun, O.İlhan, M.Özcan, S.Ayaz, K.Dalva, C.Üstün, M.Arat, M.Beksaç Serum transforming growth factor Beta 1 levels in multiple myeloma. Blood, 92(10) (Suppl2), 262b (abstrakt: 4129),1998

  67. O. Ilhan, H. Celebi, M. Arat, O. Arslan, E. Akcağlayan, C. Ustun, M. Ozcan, G. Gurman, H. Akan, N. Konuk, M. Beksac, A. Uysal, H. Koc Treatment of acute and chronic graft versus host disease with Mycophenolate Mofetil Blood, 94(10) (suppl 2) (abstrakt 4873) , 1998

  68. A. Unal, M. Cetin, B. Eser, T. Patiroglu, O. Ilhan, A. Uysal. Efficacy of non-cryopreserved autologous peripheral blood progenitor cell transplantation in lymphoma patients using a large volume single apheresis. Blood, 94(10) (suppl 2)(abstrakt: 4996), 1998

  69. Low dose Idarubicine, vincristin, prednisone and G-CSF plus ATRA for the treatment of poor risk myelodysplastic syndrome (MDS) Blood, 94(10) (suppl 2) (abstrakt:4473), 1998

  70. M. Arat, T.Demirer, C.Üstün, H.Çelebi, A.Tüzün, HS.Çoşkun, E.Ayılldız, O.İlhan, G.Gürman, M.Özcan, H.Koç.A phase I dose escalation study of high dose thiotepa, melphalan and carboplatin (TMC) followed by autologous peripheral blodd stem cell transplantation in patients with high risk brest cancer and hematologic malignancies J Clin Oncol 18: 207a, 1999

  71. O.Ilhan, T. Demirer, M. Arat, Ö. Arslan, K. Dalva, H.S. Coskun, M. Beksaç, H. Akan, M. Özcan, G. Gürman, H. Koç Platelet engraftment after allo pbsct: the role of cd41+ and cd42+ stem cells Haematologica 1999;84: P-0282

  72. C.Üstün, M. Beksaç, K. Dalva, N. Konuk, H. Koç, O. Ilhan, M. Özcan, G. Gürman, H. Akan, M. Arat,H. Çelebi, H.S. Coskun, A. Uysal The results of all-trans retinoic acid treatment on bcl2 expression and rhodamine retention in de novo aml Haematologica 1999;84:P-0979

  73. Ö. Arslan, H. Akan, M. Arat, C. Üstün, H. Çelebi, H.S. Coskun, M. Özcan, G. Gürman, O. Ihan, M. Beksaç, N. Konuk, A. Uysal, H. Koç Soluble adhesion molecules in allogeneic peripheral stem cell donors primed with rhg-csf Haematologica 1999;84: P-0850

  74. Ö. Arslan, H.S. Coskun, C. Üstün, M Arat, H. Çelebi, M. Özcan, G. Gürman, H. Akan, O. Ilhan, N. Konuk, T. Demirer, M. Beksaç, A. Uysal, H. Koç Experience of ibn-i sina hospital in allogeneic peripheral blood stem cell transplantation for standard risk leukemia patients Haematologica 1999;84: P-0283, 1999

  75. G. Gürman, H. Çelebi, C. Üstün, M Arat, O. Ilhan, M. Özcan, Ö. Arslan, A. Uysal, H. Akan, M. Beksaç, N. Konuk, H. Koç Allogeneic peripheral blood stem cell transplantation in patients with severe aplastic anemia Bone Marrow Transplant 23 (Suppl 1): 092a, 1999

  76. G. Gürman, C. Üstün, Ö. Arslan, M. Beksaç, N. Konuk, M Arat, H. Çelebi, M. Özcan, O. Ilhan, T. Demirer, H. Akan, A. Uysal, H. Koç Allogeneic hematopoietic cell transplantation in patients with advanced hematological malignancies by using nonmyeloablative conditioning regimen Bone Marrow Transplant 23 (Suppl 1): 070a, 1999

  77. T. Demirer, M Arat, H. Koç, O. Ilhan, H. Akan, G. Gürman, M. Özcan, H. Çelebi, C. Üstün, A. Uysal A protocol proposal for high-dose chemotherapy (hdc) with autologous peripheral blood stem cell transplantation (pbsct) versus conventional chemotherapy in patients with relapsed cisplatin sensitive epithelial ovarian cancer - 2 arm randomized study Bone Marrow Transplant 23 (Suppl 1): 626a, 1999

  78. T.Demirer, M Arat, H. Koç, O. Ilhan, H. Çelebi, M. Özcan, H. Akan, G. Gürman, A. Uysal A protocol proposal comparing conventional approach with high-dose chemotherapy (hdc) and peripheral blood stem cell transplantation (pbsct) in patients with small cell lung cancer limited to thorax. Bone Marrow Transplant 23 (Suppl 1): 625a, 1999

  79. O. Ilhan, T. Demirer, M Arat, K. Dalva, H.S. Coskun, M. Beksaç, H. Akan, M. Özcan, Ö. Arslan, G. Gürman, H. Koç The influence of cd41+ and cd42+ peripheral blood stem cells on platelet engraftment after allo PBSCT Bone Marrow Transplant 23 (Suppl 1): 672a, 1999

  80. M. Özcan, C. Üstün, O. Ilhan, M. Beksaç, E. Akçaglayan, G. Gürman, H. Akan, T. Demirer, M Arat, H. Çelebi, N. Konuk, A. Uysal, H. Koç The effect of G-CSF in the first 100 days of allogeneic peripheral blood stem cell transplantation Bone Marrow Transplant 23 (Suppl 1): 688a, 1999

  81. H. Akan, K. Dalva, C. Üstün, H. Çelebi, M Arat, M. Beksaç, H. Koç, O. Ilhan, G. Gürman, N. Konuk, A. Uysal Surface adhesion molecules in peripheral stem cells of healthy donors primed with G-CSF Bone Marrow Transplant 23 (Suppl 1): 644a, 1999

  82. M. Arat, T. Demirer, O. Ilhan, H. Koç, C. Üstün, H. Çelebi, E. Ayyıldız, A. Tüzün, G. Gürman, M. Özcan Peripheral blood stem cell (pbsc) collection with cyclophosphamide (cy) - paclitaxel and recombinant human granulocyte-colony stimulating factor (rhg-csf) in patients with breast cancer: ibni sina experience Bone Marrow Transplant 23 (Suppl 1): 713a, 1999

  83. C. Üstün, M. Özcan, M. Beksaç, O. Ilhan, M. Çakir, G. Gürman, Ö. Arslan, H. Akan, T. Demirer, M Arat, H. Çelebi, N. Konuk, A. Uysal, H. Koç Clinical effects of intravenous immune globuline (ivig) treatment in patients with allogeneic peripheral stem cell transplantation Bone Marrow Transplant 23 (Suppl 1): 567a, 1999

  84. O. İlhan, H. Çelebi, M Arat, Ö.Arslan, E. Akçağlayan, C.Üstün, M.Özcan, G.Gürman, H.Akan, N. Konuk, M.Beksaç, A.Uysal, H.Koç. Treatment of acute and chronic graft versus host disease with mycophenolate mofetil Blood 94 (Suppl 2 of 2):4873a, 1999

  85. M Arat, F Arpacı, A Öztürk, SB Omay, B Şahin, M Çetin, Z Başlar, S Anak, H Bilgen, S Beşışık Kalayoğlu, İ Karadoğan, B Antmen, M Bayık, S Kansoy, E Ovalı, AU Ural, O İlhan National survey of perİpheral blood stem cell (PBSC) apheresis complications in Turkey (1998) Journal of Clinical Apheresis 15(3):22a, 2000

  86. O İlhan, Ö Arslan, M Arat, M Özcan, G Gürman, K Dalva, M Beksaç, T. Demirer, N. Konuk, A. Uysal, H. Akan, H. Koç The value of peripheral blood CD34+ cell quantification in autologous hematopoietic stem cell apheresis Blood 96 (Suppl 2 of 2):79b, 2000

  87. Ö Arslan, M Arat, A Çiftçi, E Ayyıldız, O İlhan Depletion of donors erythrocytes using cell separator in major abo mismatched allogeneic bone marrow transplantation Blood 96 (Suppl 2 of 2): 325b, 2000

  88. M Arat, O İlhan, Ö Arslan, G Gürman, M Özcan, A Çiftçi, E Ayyıldız, H Koç Collection of donor lymphocytes for cellular immunotherapy Blood 96 (Suppl 2 of 2): 313b, 2000

  89. O.İlhan, Ö.Arslan, M.Arat, M.Özcan, G.Gürman, K.Dalva, M.Beksaç, T.Demirer, N.Konuk, A.Uysal, H.Koç The Value of peripheral blood CD34+ cell quantification in autologous hematopoeiteic stem cell apheresis. Blood 96 (Suppl 2 of 2): 316b, 2000

  90. T Demirer, O İlhan, M Aylı, M Arat, T Fen, R Haznedar, M Özcan, Ö Arslan, G Gürman, H Akan, M Dağlı, N Konuk, M Yıldız, G Özet, A Uysal, H Koç Phase-II study of high-dose thiotepa, melphalan and carboplatin (TMCb) with autologous peripheral blood stem cell (PBSC) support in patients with hematologic malignancies and solid tumors. Blood 96 (Suppl 2 of 2): 368b, 2000

  91. A.Ünal, M.Çetin, B.Eer, T.Patiroğlu, O.İlhan, H.Ş.Coşkun, B.Kaplan, Ö.Er, M.Altınbaş, E.Karahacioğlu. Autologous peripheral Blood Stem Cell Transplantation in Patients with Resistant And/Or Relapsing Lymphoma: Analaysis of the single center. Blood 96 (Suppl 2 of 2): 375b, 2000

  92. E.Soydan, M.Arat, C.Üstün, Ö.Arslan, D.Yazman, O.İlhan, M.Beksaç, H.Koç The incidence of avascular necrosis of the femoral head after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation 27: Suppl1:219, 2001.

  93. M.Arat, E.Soydan, Ö.Arslan, M.Özcan, G.Gürman, N.Konuk, A.Uysal, M.Beksaç, O.İlhan, H.Koç, H.Akan The long-term follw-up of lymphoma patients conditioned with CBV regimen and autologous stem cell rescue: İbni Sina experience. Bone Marrow Transplantation 27: Suppl1:265, 2001.

  94. M Arat, Arslan Ö, Ayyıldız E, Çiftçi A, İlhan O Preapheresis evaluation of platelet donors: a single center experience Transf Clin Biol 2001;8 (Suppl 1);205s:P547

  95. Arslan Ö, M Arat, Matrak M, Yazar B, Şen R, İlhan O Incidence of febrile nonhemolytic transfusion reactions to various platelet concentrates Transf Clin Biol 2001;8 (Suppl 1);125s-126s:P242

  96. M.Arat, E.Soydan, Ö.Arslan, M Özcan, G.Gürman, N.Konuk, A.Uysal, M.Beksaç, O.İlhan, H.Koç, H.Akan. The long term follow-up of lymphoma patients with CBV regimen and autologous stem cell rescue: Ibni Sina experience. 27th Annual Meeting of European Group for Blood and Marrow Transplantation, 25-28 Mart 2001, Maastricht, Hollanda. Bone Marrow Transplant 2001: 27;S265 (P679)

  97. M Özcan, M.Arat, G.Gürman, Ö.Arslan, P.Topçuoğlu, M.Beksaç, O.İlhan, N.Konuk, A.Uysal, H.Koç, H.Akan Treatment of steriod refractory GVHD with anti-thymocyte globulin 27th Annual Meeting of European Group for Blood and Marrow Transplantation, 25-28 Mart 2001, Maastricht, Hollanda. Bone Marrow Transplant 2001:27:S191

  98. Gürman G, Arat M, Soydan E, Dalva K, İlhan O, Uysal A, Beksaç M. The role of allogeneic hematopoietic cell transplantation with non-myeloablative conditioning in chronic myeloid leukemia Blood 2001;98 (part 2 of 2):375b, 5280

  99. T.Demirer, M.Aylı, M.Arat, Özcan M, N.Gunel, R.Haznedar, M.Dağlı, O.Arslan, G.Gurman, M.Dağlı, T.Fen, Y.Genç, O.İlhan, N.Konuk, H.Koç, H.Akan,. A randomized trial of assesment of efficacy of leukapheresis volumes 8 L versus 10 L. 43rd Annual Meeting of American Society of Hematology, December 7-11, 2001 Blood 2001: 98; (suppl); 330b, (5082)

  100. M.Arat, P.Topçuoğlu, E.Soydan, G.Gürman, Özcan M, Ö.Arslan, H.Koç, O.İlhan, N.Konuk, A.Uysal, M.Beksaç.A retrospective comparison of oral versus intravenous administration of busulfan: Preliminary results show similar toxicity but less relapse. 28th Annual Meeting of European Group for Blood and Marrow Transplantation, 24-27 Mart 2002, Montreoux, Bone Marrow Transpl 2002: 29: S178 (P673)

  101. Kumbasar Ö, Arat M, Beksaç M, İlhan O, Alper D, Koç H Late non-relapse mortality after allogeneic hematopoietic cell transplantation: The impact of bronchiolitis obliterans Bone Marrow Transpl 2002;29 (suppl 2): S215, P273

  102. O.Arslan, M.Arat, E.Soydan, H.S.Çoşkun, P.Topçuoğlu, M Özcan, G.Gürman, T.Demirer, O.İlhan, H.Koç, M.Beksaç, N.Konuk. A.Uysal, H.Akan. Does donor recipient ABO-incompatibility have any effects on the course and outcome of allogeneic hematopoietic cell transplantation?. 28th Annual Meeting of European Group for Blood and Marrow Transplantation, 24-27 Mart 2002, Montreoux. Bone Marrow Transpl 2002: 29: S214 (P771).

  103. İ.Yıldırım, Ö.Arslan, Y.Özer, M.Arat, E.Soydan, P.Topçuoğlu, Özcan M, G.Gürman, O.İlhan, H.Koç, M.Beksaç, A.Uysal, N.Konuk, H.Akan. The profile of erythrocyte antigens after allogeneic hematopoietic stem cell transplantation. 28th Annual Meeting of European Group for Blood and Marrow Transplantation, 24-27 Mart 2002, Montreoux. Bone Marrow Transpl 2002: 29: S239, (P 837).

  104. E.Soydan, M.Arat, O.Ozdemir Kumbasar, M Özcan, Ö.Arslan, G.Gürman, H.Koç, O.İlhan, M.Beksaç, D.Alper, H.Akan. The role of busulfan at posttransplant pulmonary complications in allogeneic hematopoietic cell transplantation. 28th Annual Meeting of European Group for Blood and Marrow Transplantation, 24-27 Mart 2002, Montreoux. Bone Marrow Transpl 2002: 29; S188

  105. C Tavat, O ArsIan, M Arat, O İlhan, M Özcan, P Topcuoglu, M Beksac, H Akan. Is there a correlation between peripheral blood CD34+ cells and peripheral blood erythrocyte precursors in healthy G-CSF stimulated donors and the effect of G-CSF and apheresis on complete blood count. 28th Annual Meeting of European Group for Blood and Marrow Transplantation, 24-27 Mart 2002, Montreoux. Bone Marrow Transpl 2002: 29; S236

  106. M Özcan, P.Topçuoğlu, M.Arat, K.Dalva, E.Soydan, Ö.Arslan, O.İlhan. Presence of tissue factor (TF) antigen expressing cells within allogeneic peripheral blood progenitor cell (PBPC) harvest. 28th Annual Meeting of European Group for Blood and Marrow Transplantation, 24-27 Mart 2002, Montreoux Bone Marrow Transpl 2002:29; S236

  107. Akyerli CB, Beksac M, Holko M, Frevel M, Dalva K, Gürman G, İlhan O, Özcan M, Akana H, Williams BRG, Özçelik T. Analysis of high and low risk chronic myeloid leukemia by gene expression profiling. 44rdAnnual Meeting of American Society of Hematology, December 6-10, 2002, Philadelphia. Blood 2002: 99;365a, (poster 1412)

  108. M.Beksac, M. Özcan, A.Tunalı, S.Dündar, M.Bayık, S.Paydaş, R.Ali, Y.Büyükbaşık, O.İlhan, F.Özkalemkaş, G.Gürman, A.Uysal, H.Akan, E.Akcaglayan, O.Özdemir. Outcome is worse in male compared to female de novo AML patients and can be improved with the use of granulocyte colony stimulating factor (G-CSF) during induction. Results of a randomized multicenter trial (Turkish Leukemia Study Group, TLG95-002). 44rdAnnual Meeting of American Society of Hematology, December 6-12, 2002, Philadelphia. Blood 2002:99; 251b, (4527)

  109. Beksac M, Arat M, Dalva K, İlhan O, Gürman G, Özcan M, Arslan Ö, Konuk N, Uysal A, Akan H. Molecular response rates achieved in chronic myelogenous leukemia (CML) patients treated with interferon, imatinib mesylate (STI) or stem cell transplantation. A single institutional experience. 44rd Annual Meeting of American Society of Hematology, December 6-12, 2002, Philadelphia. Blood 2002: 99;334b (4886)

  110. O. İlhan, M Arat, Ö Arslan, K Dalva, E Ayyıldız, H Akan. Preapheresis Dendritic Cell Count Predicts Apheresis Content In Allogeneic PBSC Collection. 44rd Annual Meeting of American Society of Hematology, December 6-12, 2002, Philadelphia. Blood 2002;100 (suppl: part 1 of 2) Abstract: 3276

  111. O. İlhan, M Arat, Ö Arslan, K Dalva, E Ayyıldız, H Akan. Preapheresis Dendritic Cell Count Predicts Apheresis Content In Allogeneic PBSC Collection. 44rd Annual Meeting of American Society of Hematology, December 6-12, 2002, Philadelphia. Blood 2002;100 (suppl: part 1 of 2) Abstract: 3276


[Başa Dön]